Takeda’s Alogliptin Falls Prey To U.S. FDA Slowdown
This article was originally published in PharmAsia News
Executive Summary
Takeda's alogliptin for type 2 diabetes has become the latest drug to face an open-ended user fee date delay, due to "internal resource constraints" at U.S. FDA